Another phase II clinical trial suggested that lenvatinib combined with toripalimab, a PD-1 inhibitor, plus Gemox chemotherapy as first-line therapy, showed good efficacy in advanced ICC, with an ORR of 80% and a median PFS of 10.0 months [17]. This evidence concerns the gene PDCD1 and intrahepatic cholangiocarcinoma.